BackgroundStage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.MethodsIn this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life.ResultsOf the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 3...
Adjuvant treatment of high-grade endometrial cancer varies greatly due to the lack of definitive res...
Background: Patients with International Federation of Gynaecology and Obstetrics (FIGO) stage III en...
Purpose: The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuv...
BACKGROUND: Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregio...
BACKGROUND: Adjuvant therapy choice for women with FIGO stage III endometrial carcinoma (EC) is cont...
Adjuvant treatment for stage III endometrial cancer is not yet defined. Previous experiences support...
Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radioth...
Background Although women with endometrial cancer generally have a favourable prognosis, those with ...
Background Although women with endometrial cancer generally have a favourable prognosis, those with ...
Abstract Objective To compare recurrence and survival in patients with stage III endometrial cancer ...
Patients with high-risk endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion > 50%, and ...
BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with...
BACKGROUND: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiot...
Objectives: Adjuvant treatment of high-risk endometrial cancer (EC) is still controversial. Several ...
Although the majority of women with endometrial cancer have a favorable prognosis due to early sympt...
Adjuvant treatment of high-grade endometrial cancer varies greatly due to the lack of definitive res...
Background: Patients with International Federation of Gynaecology and Obstetrics (FIGO) stage III en...
Purpose: The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuv...
BACKGROUND: Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregio...
BACKGROUND: Adjuvant therapy choice for women with FIGO stage III endometrial carcinoma (EC) is cont...
Adjuvant treatment for stage III endometrial cancer is not yet defined. Previous experiences support...
Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radioth...
Background Although women with endometrial cancer generally have a favourable prognosis, those with ...
Background Although women with endometrial cancer generally have a favourable prognosis, those with ...
Abstract Objective To compare recurrence and survival in patients with stage III endometrial cancer ...
Patients with high-risk endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion > 50%, and ...
BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with...
BACKGROUND: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiot...
Objectives: Adjuvant treatment of high-risk endometrial cancer (EC) is still controversial. Several ...
Although the majority of women with endometrial cancer have a favorable prognosis due to early sympt...
Adjuvant treatment of high-grade endometrial cancer varies greatly due to the lack of definitive res...
Background: Patients with International Federation of Gynaecology and Obstetrics (FIGO) stage III en...
Purpose: The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuv...